For the year, Schering's Vytorin/Zetia is off about 30 percent. . . .

Although top-line ENHANCE disappointments were already known by mid-January 2008 (post January 14), the below graph offers a perspective on just how poorly things are going for the Joint Venture's Cholesterol Franchise, this year -- the overall U.S. cholesterol management market is off about 5 percent, from January to August -- while Schering's share is down a whopping 30 percent. [Click image to enlarge.]



And this 30 percent fall-off is occuring in a drug-line that generates about 50 percent of all of Schering-Plough's profitability. Ouch.